Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 
Search Results



Your search returned 1870 record(s).

Page 81 of 187  |  Previous Page   |  Next Page

Cancer Type:   Sort By:

This Search was Made Possible by:


  Survival: Patients: Toxicity: Treatment: Hospital: Country: Date:
801 13.4 months Unresectable hepatocellular carcinoma 3 Radiation
Princess Margaret Hospital Canada 2/2008
Treatment Details: Patients: This phase I study involved 31 patients with hepatocellular carcinoma and 10 patients with intrahepatic cholangiocarcinoma. The median age of patients with liver cancer was 62, r
 
802 13.4 months Newly diagnosed GBM 3 Chemotherapy
Royal Melbourne Hospital Australia 11/2011
Treatment Details: Patients: This phase II study involved 40 newly diagnosed glioblastoma multiforme (GBM) patients who had previously received radiation therapy. The median patient 53 years and 73% of the p
 
803 13.4 months Advanced NSCLC 4 Chemotherapy
Oncological Institute Ion Chiricuta Romania 10/2009
Treatment Details: Patients: This phase 3 study involved 663 patients with advanced non-small cell lung cancer. The median age was 60, ranging from 53 to 67 years. The majority (73%) were men. Treatment
 
804 13.4 months Castration-resistant prostate cancer 4 Chemotherapy
University of Maryland Greenebaum Cancer Center United States 3/2009
Treatment Details: Patients: This phase 2 study involved 45 men with castration-resistant prostate cancer. The median age was 69, ranging from 52 to 84 years of age. Treatment: Patients were treated with
 
805 13.4 months Recurrent or progressing GBM Biologic therapy
Drexel University College of Medicine United States 1/2002
Treatment Details: Patients: This Phase II study involved 180 patients with high grade glioma. The patient population consisted of 118 patients with glioblastoma multiforme, 55 with anaplastic astrocytoma foc
 
806 13.4 months Hormone refractory prostate cancer 4 Chemotherapy
Georges Pompidou European Hospital France 5/2005
Treatment Details: Patients: This Phase II study enrolled 130 men, who were randomized into three groups. Group C had 42 men (median age 70) with hormonal-resistant prostate cancer. One patient had metastati
 
807 13.4 months HER2-negative advanced breast cancer 5 Biologic therapy
Chemotherapy
Memorial Sloan-Kettering Cancer Center United States 5/2013
Treatment Details: Patients: This phase 2 study involved female HER2-negative advanced breast cancer patients previously treated with bevacizumab who were divided into two separate treatment groups patients.
 
808 13.4 months GBM 5 Chemotherapy
Radiation
UAB Department of Neurology United States 5/2015
Treatment Details: Patients: This phase 2 study involved unmethylated MGMT gene promoter glioblastoma patients who were divided into two separate treatment groups. Group A had 88 patients with a median age of
 
809 13.4 months Metastatic, Castration-Resistant Prostate Cancer 4 Chemotherapy
The Royal Melbourne Hospital Australia 6/2015
Treatment Details: Patients: This study involved 20 elderly metastatic castration-resistant prostate cancer patients with a median age of 83 years (range: 80-93). Treatment: Patients received chemotherapy
 
810 13.4 months NSCLC 5 Biologic therapy
Chemotherapy
Robert H. Lurie Comprehensive Cancer Center United States 12/2013
Treatment Details: Patients: This phase 3 study involved nonsquamous non-small cell lung cancer patients who were divided into two separate treatment groups. Group A consisted of 472 patients with a median ag
 
Page 81 of 187  | Previous Page  | Next Page